- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00057577
Prevention of Recurrence in Depression With Drugs and CT (CPT3)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
It is commonly believed that the combination of ADM and psychotherapy is more effective in treating depression than either treatment alone. Data indicate that CT enhances the initial effects of ADM, but little research has been conducted to determine whether prior exposure to CT prevents the onset of new depressive episodes. This study will determine the effectiveness of adding CT to ADM for the treatment of depression.
Participants are randomly assigned to receive either ADM alone or ADM plus CT for up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue cognitive therapy; all recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Rush Medical Center - Treatment Research Unit
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Depression Research Unit, University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Vanderbilt Adult Outpatient Psychiatry
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Recurrent or chronic major depressive disorder
Exclusion Criteria:
- Current diagnosis of psychotic affective disorder
- History of nonaffective psychotic disorder
- Substance dependence last three months requiring detox
- Schizotypal, antisocial, or borderline personality disorder
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Cognitive therapy plus medications
Participants will receive antidepressant medication plus cognitive therapy
|
CT sessions occur weekly during acute treatment and monthly during continuation.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery.
At recovery, patients receiving combined treatment discontinue CT.
Altri nomi:
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Altri nomi:
|
Sperimentale: Medications alone
Participants will receive maintenance of antidepressant medication alone
|
Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed.
Acute treatment may last up to 18 months.
Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery.
All recovered patients are randomized a second time to either maintenance medication or medication withdrawal.
Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants in Remission According to the Longitudinal Interval Follow-up Evaluation (LIFE) and the Hamilton Rating Scale for Depression (HRSD)
Lasso di tempo: Through month 18 of treatment
|
Remission defined as four consecutive weeks of LIFE Problem Symptom Rating (PSR) values of 2 or less and HRSD scores of 8 or less for four consecutive weeks (with partial remission defined as LIFE PSR values of 3 or less and HRSD scores of 12 or less after month 12 only)
|
Through month 18 of treatment
|
Number of Participants in Recovery According to the LIFE and HRSD
Lasso di tempo: Through 36 months of treatment
|
Six consecutive months following remission without relapse (two weeks of elevated LIFE PSR scores of 4 or more and HRSD scores of 14 and above)
|
Through 36 months of treatment
|
Number of Participants in Recurrence According to the LIFE and HRSD
Lasso di tempo: Measured up to Month 36 from recovery
|
Recurrence defined as two consecutive weeks of elevated LIFE PSR scores of 5 or above and HRSD scores of 16 or above (three weeks during period of medication withdrawal)
|
Measured up to Month 36 from recovery
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Serious Adverse Events
Lasso di tempo: Throughout study, up to 54 months
|
Number Serious Adverse Events (SAEs) as reported to the Institutional Review Boards and Data Safety Monitoring Board throughout the duration of the study
|
Throughout study, up to 54 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Steven D. Hollon, PhD, Vanderbilt University
- Investigatore principale: Jan A. Fawcett, MD, Rush Medical Center
Pubblicazioni e link utili
Pubblicazioni generali
- Khazanov GK, Xu C, Hollon SD, DeRubeis RJ, Thase ME. Adding cognitive therapy to antidepressant medications decreases suicidal ideation. J Affect Disord. 2021 Feb 15;281:183-191. doi: 10.1016/j.jad.2020.12.032. Epub 2020 Dec 8.
- Khazanov GK, Xu C, Dunn BD, Cohen ZD, DeRubeis RJ, Hollon SD. Distress and anhedonia as predictors of depression treatment outcome: A secondary analysis of a randomized clinical trial. Behav Res Ther. 2020 Feb;125:103507. doi: 10.1016/j.brat.2019.103507. Epub 2019 Oct 31.
- DeRubeis RJ, Zajecka J, Shelton RC, Amsterdam JD, Fawcett J, Xu C, Young PR, Gallop R, Hollon SD. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020 Mar 1;77(3):237-245. doi: 10.1001/jamapsychiatry.2019.3900. Erratum In: JAMA Psychiatry. 2020 Jan 29;:
- Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014 Oct;71(10):1157-64. doi: 10.1001/jamapsychiatry.2014.1054.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R01MH060713 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cognitive Therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Reclutamento
-
University of AmsterdamAcademic Center for Trauma and Personality; Arkin Mental Health CareIscrizione su invitoDisturbo borderline di personalitàOlanda
-
EP SciencesSconosciutoElettrofisiologia cardiacaStati Uniti
-
Medical University of South CarolinaNational Institute on Deafness and Other Communication Disorders (NIDCD)Attivo, non reclutanteIctus | Afasia | Afasia non fluenteStati Uniti
-
Karadeniz Technical UniversityCompletatoEmodialisi | Solitudine | Felicità | Adattamento | Terapia assistita da animali | SintomoTacchino
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale Hochschule...Completato
-
Zealand University HospitalUniversity of Copenhagen; Technical University of Denmark; OptoCeuticsCompletatoMalattia di AlzheimerDanimarca
-
University of Roma La SapienzaCompletatoImpianto dentale fallito | Mucosite OraleItalia
-
GGZ CentraalUtrecht UniversityCompletatoDisturbi della personalità | Disturbi dell'umore | Disturbi d'ansia | IncubiOlanda
-
Sheffield Teaching Hospitals NHS Foundation TrustCompletato